View More View Less
  • 1 Egyesített Szent István és Szent László Kórház-Rendelőintézet, Budapest, Albert Flórián út 5–7., 1097
Full access

Absztrakt:

A Waldenström-féle macroglobulinaemia egy jellemzően a csontvelőben terjedő lymphoplasmocytás lymphoma és következményes monoklonális IgM-hiperszekréció okozta klinikai tünetegyüttes. A közelmúlt eredményei rámutattak, hogy a betegség legalább három eltérő patobiológiájú és klinikai viselkedésű formájában jelentkezhet. A MYD88 95–97%-os gyakoriságú mutációi mellett 30–40%-os gyakorisággal megjelenhetnek CXCR4-mutációk, 17%-ban ARID1A-mutációk és 10% körüli gyakorisággal CD79B-mutációk. A CXCR-jelátvitel képes a MYD88-aktiváció fokozta tumorszuppresszorgén-működés elnémítására. A MYD88- és CXCR4-mutációk együttes előfordulása nagyobb tumortömeget, kezeléskor lassabban kialakuló és kevésbé mély választ eredményez, gyakoribb rezisztenciával. Összefoglalónkban a legújabb adatok birtokában kívánunk támpontot nyújtani a szimptomatikus betegség kezelésekor megkívánt kezelési protokoll megválasztásához. Orv Hetil. 2017; 158(41): 1604–1614.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Tímár B. The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia. [A lymphoplazmocitás limfóma/Waldenström-makroglobulinémia patológiája és genetikája.] Magy Onkol. 2017; 61: 6–11. [Hungarian]

  • 2

    Mucsi OA, Nagy Zs. How can we treat Waldenström’s macroglobulinemia? [Újdonságok a Waldenström-makroglobulinémia kezelésében.] Magy Onkol. 2017; 61: 12–20. [Hungarian]

  • 3

    Hanzis C, Ojha RP, Hunter Z, et al. Associated malignancies in patients with Waldenström’s macroglobulinemia and their kin. Clin. Lymphoma Myeloma Leuk. 2011; 11: 89–92.

  • 4

    Treon SP, Tripsas C, Hanzis C, et al. Familial diasease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2012; 12: 433–437.

  • 5

    Hunter ZR, Yang G, Xu L, et al. Genomics, signaling and treatment of Waldenström macroglobulinemia. J Clin Oncol. 2017; 35: 994–1001.

  • 6

    Ocio EM, Schop RF, Gonzales B, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007; 136: 80–86.

  • 7

    Avet-Loiseau H, Garand R, Lodé L, et al. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom’s macroglobulinemia. Semin Oncol. 2003; 30: 153–155.

  • 8

    Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014; 123: 1637–1646.

  • 9

    Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012; 367: 826–833.

  • 10

    Lin SC, Lo YC, Wu H. Helical assembly in the MyD88:IRAK4: IRAK2 complex in TLR/IL-1R signaling. Nature 2010; 465: 885–890.

  • 11

    Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Engl J Med. 2015; 373: 584–586.

  • 12

    Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014; 167: 506–513.

  • 13

    Treon SP, Tsakmaklis N, Meid K, et al. Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom’s macroglobulinemia. Blood 2016; 128: 2984.

  • 14

    Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood 2014; 123: 2791–2796.

  • 15

    Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia. Clin Cancer Res. 2016; 22: 1480–1488.

  • 16

    Liu Q, Chen H, Ojode T, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 2012; 120: 181–189.

  • 17

    Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia. Br J Haematol. 2016; 172: 735–744.

  • 18

    Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemia. Leukemia 2015; 29: 169–176.

  • 19

    Alonso S, Jimenez C, Alcoceba M, et al. Whole-exome sequencing of Waldenström macroglobulinemia transformation into agressive lymphoma. Blood 2016; 128: 4101.

  • 20

    Sekhar J, Sanfilippo K, Morgensztern D, et al. Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012; 53: 1625–1626.

  • 21

    Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015; 169: 81–89.

  • 22

    Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009; 113: 4163–4170.

  • 23

    Kastritis E, Gavriatopulou M, Kyrtsonis MC, et al. A revised staging system for Waldenström’s macroglobulinemia. EHA Oral Presentation 2017, Abstract S415. learnincenter.ehaweb.org/eha/2017/22nd/181702/efstathios.kastritis.a.revised.staging.system.for.waldenstrm.s.macroglobulinemia.html

  • 24

    Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124: 1404–1411.

  • 25

    Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003; 30: 116–120.

  • 26

    Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003; 30: 110–115.

  • 27

    Gustine JN, Meid K, Dubeau T, et al. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017; 177: 717–725.

  • 28

    Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia. MAYO stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017 Jan 5. [Epub ahead of print]

    • Crossref
    • Export Citation
  • 29

    Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017; 92: 838–850.

  • 30

    Ansell SM, Kyle RA, Morice WG, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010; 85: 824–833.

  • 31

    Treon SP, Hanzis C, Hunter ZR, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011; 154: 357–362.

  • 32

    Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2016; 6: e391.

  • 33

    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007; 25: 3344–3349.

  • 34

    Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009; 27: 3830–3835.

  • 35

    Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood 2014; 124: 503–510.

  • 36

    Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005; 23: 3383–3389.

  • 37

    Olszewski AJ, Chen C, Gutman R, et al. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 Jul 5. [Epub ahead of print]

    • Crossref
    • Export Citation
  • 38

    Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011; 11: 133–135.

  • 39

    Rummel MJ, Niederle N, Maschmeyer G, et al., on behalf of the Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210.

  • 40

    Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 62–66.

  • 41

    Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2015; 5: e394.

  • 42

    Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Br J Haematol. 2017; 179: 98–105.

  • 43

    Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009; 113: 3673–3678.

  • 44

    Tedeschi A, Benevolo G, Visco C, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118: 434–443.

  • 45

    Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015; 372: 1430–1440.

  • 46

    Abeykoon JP, Yanamandra U, Kapoor P. New developments in the management of Waldenström macroglobulinemia. Cancer Manag Res. 2017; 9: 73–83.

  • 47

    Treon SP. How I treat Waldenström macroglobulinemia. Blood 2015; 126: 721–732.

  • 48

    Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010; 28: 2227–2232.

  • 49

    Mikala G, Ceglédi A, Csukly Z, et al. High-dose therapy fallowed by autologous stem cell transplantation is an exceptionally effective therapy in Waldenström’s macroglobulinemia [A nagy dózisú terápiát követő autológ őssejt-átültetés a Waldenström macroglobulinemia kiemelkedően eredményes terápiás lehetősége. Hematol Transzfúz. 2016; 49: S56. [Hungarian]

  • 50

    Paulus A, Akhtar S, Yousaf H, et al. Waldenstrom macroglobulinemia cells devoid of BTK C481S or CXCR WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017; 7: e565.

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION